Gastrointestinal Cancers

GI cancers encompass colorectal, gastric/GEJ, hepatocellular, pancreatic, biliary tract, and GIST cancers. Immunotherapy, HER2-targeted therapy, FGFR2 inhibitors, and RAS-targeted agents are reshaping treatment across these histologies.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Gastrointestinal Cancers

• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Nivolumab (Opdivo) — Checkpoint Inhibitor
• Trastuzumab deruxtecan (Enhertu) — Antibody-Drug Conjugate
• Ramucirumab (Cyramza) — Monoclonal Antibody
• Bevacizumab (Avastin) — Monoclonal Antibody
• Cetuximab (Erbitux) — Monoclonal Antibody
• Panitumumab (Vectibix) — Monoclonal Antibody
• Regorafenib (Stivarga) — Tyrosine Kinase Inhibitor
• Irinotecan (Camptosar) — Topoisomerase Inhibitor
• Oxaliplatin (Eloxatin) — Alkylating Agent
• 5-Fluorouracil (5-FU) (Adrucil) — Antimetabolite
• Capecitabine (Xeloda) — Antimetabolite
• Atezolizumab (Tecentriq) — Checkpoint Inhibitor
• Futibatinib (Lytgobi) — Tyrosine Kinase Inhibitor
• Pemigatinib (Pemazyre) — Tyrosine Kinase Inhibitor
• Sorafenib (Nexavar) — Tyrosine Kinase Inhibitor
• Lenvatinib (Lenvima) — Tyrosine Kinase Inhibitor
• Zanidatamab (Ziihera) — Other